Product Pipeline

Program Mechanism of Action
(Modality)
Indication Preclinical Phase 1 Phase 2 Phase 3

HS-110

gp96 + CTAs
(Cell Therapy)
NSCLC
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

HS-130

OX40L
(Cell Therapy)
SOLID TUMORS
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started

COVID-19 Vaccine

gp96 + Viral
Antigens
(Cell Therapy)
COVID-19
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

PTX-35

TNFRSF25
(Antibody)
SOLID TUMORS
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started

CTA = Cancer testis antigens; NSCLC = Non-small cell lung cancer